TJPC(SH:600488) Ge Long Hui·2026-02-12 08:40Core Viewpoint - Company and its subsidiaries participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for the continuation of procurement [1] Group 1: Procurement Details - The national procurement office announced the proposed selection results for the continuation of procurement on February 10, 2026 [1] - The procurement cycle for selected drugs will last from the execution date of the selection results until December 31, 2028 [1] Group 2: Financial Impact - The total sales revenue from the selected drugs for the year 2024 is projected to be RMB 323 million, accounting for 10.03% of the company's revenue during the same period [1] - The sales revenue for the first three quarters of 2025 is estimated to be RMB 250 million (unaudited), representing 11.20% of the company's revenue for that period [1]